Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 337 (miR-337)
- Target
- miR-337
- Molecular classification
- MicroRNA family, Non-coding RNA, Other
01
Overview
MicroRNA 337 is a small, non-coding RNA molecule that functions primarily as a post-transcriptional regulator of gene expression. It is transcribed from the human genome as a precursor molecule, which is subsequently processed into mature miR-337. miR-337 acts as a tumor suppressor in multiple cancer types, typically by downregulating genes involved in cell proliferation, migration, invasion, and adhesion, and by promoting apoptosis. Specific targets include cyclin-dependent kinase 1 (CDK1) in breast cancer[1] and matrix metalloproteinase 14 (MMP-14) in neuroblastoma[2]. miR-337 is under-expressed in several human cancers, and its upregulation suppresses tumor progression and metastasis[1][2]. High expression of miR-337 is associated with favorable outcomes in various malignancies, making it a promising therapeutic target and prognostic biomarker.
- Other names
- MIR337hsa-mir-337MIRN337mir-337
02
Mechanism of action
Direct repression of target mRNAs by binding to their 3′-UTR. Transcriptional repression by binding gene promoters and recruiting Argonaute 2 for chromatin modification and reduced transcription (notably for MMP-14 in neuroblastoma). Sensitization of cancer cells to chemotherapy by modulating key survival pathways.
03
Biological functions
Post-transcriptional regulation of gene expression[3]Inhibition of cell proliferation, adhesion, migration, invasion, and promotion of apoptosis in cancer cells[1][2]Transcriptional repression (binds gene promoters and mediates epigenetic suppression, e.g., MMP-14)[2]
04
Disease associations
Cancer (breast cancer, neuroblastoma, hepatocellular carcinoma, non-small cell lung cancer, cervical cancer, clear cell renal cell carcinoma, gastric cancer, colon cancer, medulloblastoma, ovarian cancer, oral squamous cell carcinoma)[1][2][3]Metastasis and tumor aggressiveness[1][2]Other (potential involvement in development due to localization within imprinted regions)[2]
05
Safety considerations
Manipulation of miRNA levels can impact multiple pathways; off-target effects and genomic instability are potential concerns[2]Tissue-specific expression means miR-337-based therapeutic strategies may have variable efficacy and safety in different cancers[2]
06
Interacting drugs
Paclitaxel
2 more in the full profile.
07
Biomarkers
miR-337-3p expression is used as a biomarker for prognosis and disease progression in several cancers; high expression correlates with better survival, lower tumor aggressiveness, and reduced metastatic potential[1][2]Expression levels in serum or tumor tissue are biomarker candidates for breast cancer, neuroblastoma, and others[1][2]
Beyond the preview
Go deeper on MicroRNA 337 (miR-337).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 337 (miR-337).